Professor Li Huiping: Precision Systemic Treatment for Breast Cancer
Professor Li Huiping is a senior medical oncologist, professor, and doctoral supervisor at Peking University Cancer Hospital. Her clinical and academic work focuses on individualized systemic treatment for breast cancer, including HER2-positive, hormone receptor-positive, and triple-negative disease.
International patients can learn more about the hospital, pathology requirements, and treatment planning in our Peking University Cancer Hospital international patient guide.
Clinical Specialties
- early and locally advanced breast cancer;
- metastatic or recurrent breast cancer;
- HER2-positive breast cancer;
- hormone receptor-positive breast cancer;
- triple-negative breast cancer;
- neoadjuvant and adjuvant therapy;
- targeted therapy, endocrine therapy, chemotherapy, and immunotherapy;
- treatment after resistance or recurrence; and
- clinical-trial evaluation.
Breast Cancer Subtypes
Breast cancer treatment depends on pathology and biomarkers rather than stage alone. Core testing commonly includes estrogen receptor, progesterone receptor, HER2, and Ki-67. Selected patients may also need germline genetic testing or broader tumor profiling.
Pathology review is particularly useful when receptor results are borderline, samples from different sites disagree, or the disease has changed after treatment.
HER2-Positive Breast Cancer
HER2-positive tumors may respond to HER2-directed medicines used with chemotherapy or in other combinations. Treatment selection depends on stage, previous therapy, heart function, brain involvement, response, toxicity, and local approval.
For metastatic disease, antibody-drug conjugates and other HER2-directed strategies have expanded treatment options. These therapies still require careful monitoring for effects such as low blood counts, heart dysfunction, or lung inflammation.
Hormone Receptor-Positive Breast Cancer
Hormone receptor-positive disease is commonly treated with endocrine therapy. Depending on the setting, treatment may be combined with ovarian suppression, CDK4/6 inhibitors, or other targeted medicines.
Menopausal status, recurrence risk, bone health, tumor genomics, prior therapy, and resistance patterns influence the plan. Endocrine treatment may continue for years, so side-effect management and adherence matter.
Triple-Negative Breast Cancer
Triple-negative breast cancer lacks estrogen receptor, progesterone receptor, and HER2 expression by standard definitions. It can behave aggressively, but it is also biologically diverse.
Treatment may include chemotherapy, immunotherapy for selected patients, surgery, radiotherapy, antibody-drug conjugates, PARP inhibitors for certain inherited mutations, or clinical trials. PD-L1 and germline BRCA testing may be relevant depending on stage and treatment setting.
Neoadjuvant and Adjuvant Treatment
Systemic treatment before surgery can shrink a tumor, provide information about treatment response, and guide postoperative therapy. Treatment after surgery aims to reduce recurrence risk.
The sequence should be planned by a multidisciplinary team. Starting surgery immediately is not always best for HER2-positive, triple-negative, or locally advanced disease.
Metastatic Breast Cancer
Metastatic breast cancer is generally treated as a chronic systemic disease. The aim is to control cancer, relieve symptoms, preserve function, and extend survival while managing toxicity.
Biopsy of a metastatic site may be useful because receptor status can change. Treatment choice also depends on the location and pace of disease, symptoms, previous response, organ function, and patient priorities.
Who May Consider a Consultation?
- patients with newly diagnosed high-risk or locally advanced breast cancer;
- patients needing a second opinion on treatment before or after surgery;
- patients with recurrent or metastatic disease;
- patients whose ER, PR, or HER2 results are uncertain or have changed;
- patients whose cancer progressed after endocrine, HER2-directed, immune, or chemotherapy treatment;
- patients with brain, liver, lung, or bone metastases requiring multidisciplinary review; or
- patients assessing molecular testing or clinical-trial options.
Medical Records to Prepare
- a concise medical summary and exact treatment timeline;
- mammography, ultrasound, breast MRI, CT, PET-CT, and brain MRI in original format;
- pathology reports, glass slides, and paraffin blocks;
- ER, PR, HER2, Ki-67, PD-L1, germline, and tumor-sequencing reports;
- operative and radiotherapy records;
- every systemic treatment with dates, doses, response, and toxicity;
- recent blood count, liver and kidney function, and cardiac assessments;
- current symptoms and performance status; and
- a clear list of treatment priorities and questions.
Planning an International Consultation
Before traveling, patients should confirm whether records, imaging, and pathology can be reviewed and whether additional testing is required. Remote medical-record review is subject to physician authorization, and final treatment or clinical-trial eligibility requires complete specialist assessment.
How CMCS Can Assist
CMCS – China Medical Concierge Shanghai is an independent medical concierge and health management company, not a hospital. We assist international patients with organizing and translating oncology records, identifying an appropriate specialist, requesting appointment availability, arranging interpretation, and planning medical travel in China.
Access to Professor Li, remote review, a particular medicine, or clinical trials is subject to the doctor’s and hospital’s approval. CMCS does not guarantee appointments, treatment eligibility, trial enrollment, or clinical outcomes.
- Email: contract@medicalsh.com
- WhatsApp: Contact us on WhatsApp
- Website: www.medicalsh.com
Important Note
Doctor roles, biomarker requirements, medicine approvals, trial availability, and appointment arrangements may change. This profile is for general information only and does not replace assessment by a qualified breast oncology team.
0 Kommentare